GMED Q2 Deep Dive: New CEO, Nevro Integration, and Product Pipeline Propel Growth

Medical device company Globus Medical reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 18.4% year on year to $745.3 million. The company expects the full year’s revenue to be around $2.85 billion, close to analysts’ estimates. Its non-GAAP profit of $0.86 per share was 14.1% above analysts’ consensus estimates.

Is now the time to buy GMED? Find out in our full research report (it’s free).

Globus Medical (GMED) Q2 CY2025 Highlights:

• Revenue: $745.3 million vs analyst estimates of $740.2 million (18.4% year-on-year growth, 0.7% beat)
• Adjusted EPS: $0.86 vs analyst estimates of $0.75 (14.1% beat)
• Adjusted EBITDA: $208.7 million vs analyst estimates of $199.1 million (28% margin, 4.8% beat)
• The company reconfirmed its revenue guidance for the full year of $2.85 billion at the midpoint
• Management reiterated its full-year Adjusted EPS guidance of $3.15 at the midpoint
• Operating Margin: 10.2%, up from 7.9% in the same quarter last year
• Constant Currency Revenue rose 17.6% year on year (117% in the same quarter last year)
• Market Capitalization: $7.92 billion

StockStory’s Take

Globus Medical delivered results that exceeded Wall Street’s expectations in the second quarter, with the market responding favorably to its 18.4% revenue growth and improved profitability. Management credited the strong performance to the resurgence of its U.S. Spine business, new product launches, and the successful resolution of earlier supply chain constraints. CEO Keith Pfeil highlighted the positive momentum in core trauma and enabling technologies, noting, “Our U.S. Spine business led the way commercially, growing 5.7% as reported.” Recent acquisitions and operational improvements also contributed to the company’s performance this quarter.

Looking ahead, Globus Medical’s outlook is anchored by accelerating product development, expanded manufacturing initiatives, and the ongoing integration of Nevro. Management cited a robust pipeline of new products and a focus on operational efficiency as key drivers of anticipated future growth. CFO Kyle Kline expressed confidence that synergy actions and manufacturing improvements will drive margin expansion, while Pfeil emphasized the company’s intent to “develop new tools within the R&D pipeline and achieve market share gains.” The company is also preparing for the commercial rollout of its augmented reality navigation headset, aiming to strengthen its presence in musculoskeletal care.

Key Insights from Management’s Remarks

Management attributed the quarter’s results to the strength of its U.S. Spine and trauma businesses, successful product launches, and the initial impacts of integrating Nevro. The leadership transition and operational focus were also highlighted as central to driving performance.

• Leadership transition completed: Keith Pfeil was promoted to CEO, succeeding Dan Scavilla, while Kyle Kline became CFO. Both transitions were internally planned, aiming to maintain continuity and deepen operational focus following recent acquisitions.
• U.S. Spine and trauma growth: The U.S. Spine business demonstrated consistent weekly growth, supported by strong adoption of key products like SABLE implants and Reline MAS. Core trauma showed rapid expansion, especially from the AUTOBAHN nail and ANTHEM plate lines.
• Nevro integration underway: The acquisition of Nevro added spinal cord stimulation and pain management solutions. Early integration efforts focused on cost controls, recasting product development, and energizing the sales force, with management targeting mid-term profitability improvements.
• Supply chain recovery: Management reported that supply issues from earlier in the year were largely resolved, enabling improved delivery of spine sets and inventory throughout the U.S. and internationally, positioning the business for sustained growth.
• Product innovation pipeline: The company launched 21 new products since the start of the year, including the ONVOY Acetabular System for hip reconstruction and the DuraPro oscillating drill. The recent FDA clearance for the Excelsius XR augmented reality headset signals further expansion in surgical technology.

Drivers of Future Performance

Globus Medical’s forward strategy centers on manufacturing enhancements, continued integration of acquired businesses, and a steady cadence of product innovation to support growth and margin improvement.

• Manufacturing and margin focus: Management is prioritizing initiatives to expand in-house manufacturing, with the goal of returning gross margins to the mid-70% range over the next year. These efforts are expected to reduce costs and improve profitability, although leadership noted the cadence of benefits will ramp through 2026 as new equipment and processes mature.
• Nevro synergy realization: The ongoing integration of Nevro remains a key focus, with leadership targeting operational synergies—especially in SG&A and R&D—to drive earnings accretion. Management acknowledged risks tied to sales retention as cost actions are implemented, but believes stable leadership and a unified commercial approach will enable gradual sales stabilization.
• Product pipeline and technology adoption: Ongoing investment in R&D is fueling new launches such as the Excelsius XR headset and expanded joint reconstruction offerings. Management believes these innovations will support competitive differentiation and growth, particularly as robotic and navigation systems see greater adoption in musculoskeletal procedures.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will monitor (1) the pace of Nevro integration and resulting cost synergies in both SG&A and R&D, (2) adoption rates for new enabling technology products, including the Excelsius XR headset, and (3) sustained momentum in the U.S. Spine and trauma segments as new products and sales initiatives are rolled out. Execution in international market integration and manufacturing upgrades will also be important signposts.

Globus Medical currently trades at $58.87, up from $54.12 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return).

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.